Aptamer-based Targeted Delivery of miRNA let-7d to Gastric Cancer Cells as a Novel Anti-Tumor Therapeutic Agent

Authors

  • Ali Elmi Medical Biotechnology Research Center, School of paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Iraj Nikokar Medical Biotechnology Research Center, School of paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Korosh Khanaki Medical Biotechnology Research Center, School of paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Mahsa Ramezanpour Medical Biotechnology Research Center, School of paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Maryam Tabarzad Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Mojtaba Hedayati CH Department of Medical Microbiology, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Puyan Daei Medical Biotechnology Research Center, School of paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
Abstract:

miRNAs as one of the potential therapeutic agents have been recently considered for cancer treatment. AS1411 (aptNCL) is a DNA aptamer specifically binding to nucleolin protein on the cancer cell surface with antiproliferative effect. The aim of the study was to develop a conjugate consisted of aptNCL (as targeted delivery of therapeutic agent) and miRNA let-7d (as a tumor suppressor) using two different linking methods and also to evaluate the potential effect of the conjugates on the proliferation of gastric cancer (MKN-45) cell line compared to negative control cell line of human dermal fibroblast (HDF). Conjugation was performed covalently by SM(PEG)2 as a bifunctional crosslinker (conjugate-1) and noncovalently using 19bp complementary sticky end sequences (conjugate-2), respectively. Nucleolin positive MKN-45 and nucleolin negative HDF cells were cultured and treated with the conjugates. Then, the changes in let-7d expression and cell proliferation were determined using Real-time PCR and MTT methods, respectively. In MKN-45 cells, the conjugates caused significantly increase in let7-d uptake compared with HDF cells (p=0.0001). The conjugate-1, likely due to its higher stability compared with the conjugate-2, led to significantly more increase in intracellular let-7d in MKN-45 cells (30 fold versus 15 fold, respectively, p=0.0001). The conjugates revealed more potent antiproliferative effect against gastric cancer cells compared with aptNCL alone (p=0.0001). It was found that the aptNCL-let-7d conjugate efficiently carried let-7d into the cancer cells. Also, it appears that in the setting of aptNCL-let-7d conjugate, let-7d and aptNCL moieties could cooperate and synergistically exhibit the antiproliferative effect on cancer cells.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells

Accumulating evidence indicates that a small subset of cancer cells, termed the tumor-initiating cells or cancer stem cells (CSCs), construct a reservoir of self-sustaining cancer cells with the characteristic ability to self-renew and maintain the tumor mass. The CSCs play an important role in the tumor initiation, development, relapse, metastasis, and the ineffectiveness of conventional cance...

full text

Aptamer-Targeted DNA Nanostructures for Therapeutic Delivery

DNA-based nanostructures have been widely used in various applications due to their structural diversity, programmability, and uniform structures. Their intrinsic biocompatibility and biodegradability further motivates the investigation of DNA-based nanostructures as delivery vehicles. Incorporating AS1411 aptamers into DNA pyramids leads to enhanced intracellular uptake and selectively inhibit...

full text

Doxorubicin Loaded DNA Aptamer Linked Myristilated Chitosan Nanogel for Targeted Drug Delivery to Prostate Cancer

Recently, specific attention has been paid to aptamers, short DNA or RNA, as a tool for cancer diagnosis and therapy. In the present study MCS nanogels were prepared by Myristate: chitosan at 1:9 ratio and were characterized by several techniques. A selected ssDNA aptamer(Apt) capable of detecting LNCaP cells was linked to Myristilated chitosan nanogels (Apt-MCS) by glutaraldehyde and loaded wi...

full text

Doxorubicin Loaded DNA Aptamer Linked Myristilated Chitosan Nanogel for Targeted Drug Delivery to Prostate Cancer

Recently, specific attention has been paid to aptamers, short DNA or RNA, as a tool for cancer diagnosis and therapy. In the present study MCS nanogels were prepared by Myristate: chitosan at 1:9 ratio and were characterized by several techniques. A selected ssDNA aptamer(Apt) capable of detecting LNCaP cells was linked to Myristilated chitosan nanogels (Apt-MCS) by glutaraldehyde and loaded wi...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 17  issue 4

pages  1537- 1549

publication date 2018-10-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023